A Phase III Clinical Trial Evaluating Dcvax?-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multifor
Posted Date: May 15, 2019
- Investigator: Rekha Chaudhary
- Type of Study: Drug
This study will determine whether DCVax-Brain can slow growth and recurrence of brain tumors and whether it can extend overall survival. Participating patients will be treated with the study drug or placebo. Treatment can last up to 36 months. Patients will be followed-up for the rest of their lives
Criteria:
Eligible Patients Must Have A Brain Tumor
Keywords:
20221, Brain Cancer, Brain Tumor, Gbm, Glioblastoma Multifo
For More Information:
Uc Cancer Center
513-584-7698
kastla@ucmail.uc.edu